Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: Sequence specificity and structural drug determinants

Cancer Research

Volumn 57, Issue 9, 1997, Pages 1710-1716

  Binaschi, Monica ^a   Zagotto, Giuseppe ^b   Palumbo, Manlio ^b   Zunino, Franco ^a   Farinosi, Rosalba ^a   Capranico, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CLEROCIDIN A; CYTOSINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GUANINE; RUFOCROMOMYCIN; SODIUM CHLORIDE; TENIPOSIDE; TERPENOID; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA SEQUENCE; DRUG DNA INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CYTOTOXINS; DITERPENES; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DNA, VIRAL; ETHANOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; TUMOR CELLS, CULTURED;

EID: 0030965935     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
2. Pommier, Y., and Kohn, K. W. Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: R. I. Glazer (ed.), Developments in Cancer Chemotherapy, pp. 175-195. Boca Raton, FL: CRC Press, 1989.
3. Osheroff, N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther., 41: 223-241, 1989.
4. Capranico, G., and Zunino, F. Antitumor inhibitors of DNA topoisomerases. Curr. Pharm. Des., 1: 1-14, 1995.
5. Gellert, M. DNA topoisomerase. Annu. Rev. Biochem., 50: 879-910, 1981.
6. Lock, R. B., and Ross, W. E. DNA topoisomerases in cancer therapy. Anti-Cancer Drug Des., 2: 151-164, 1987.
7. Wang, J. C. DNA topoisomerases: why so many? J. Biol. Chem., 266: 6659-6662, 1991.
8. Roca, J. The mechanisms of DNA topoisomerases. Trends Biochem. Sci., 20: 156-160, 1995.
9. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
10. Borgnetto, M. E., Zunino, F., Tinelli, S., Kas, E., and Capranico, G. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin. Heterogeneous localization and reversibility. Cancer Res., 56: 1855-1862, 1996.
11. Capranico, G., Kohn, K. W., and Pommier, Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res., 18: 6611-6619, 1990.
12. Fosse, P., Rene, B., Le Bret, M., Paoletti, C., and Saucier, J. M. Sequence requirements for mammalian topoisomerase II-mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res., 19: 2861-2868, 1991.
13. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide (published erratum in Nucleic Acids Res., 19: 7003, 1991). Nucleic Acids Res., 19: 5973-5980, 1991.
14. Capranico, G., Palumbo, M., Tinelli, S., Mabilia, M., Pozzan, A., and Zunino, F. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J. Mol. Biol., 235: 1218-1230, 1994.
15. Freudenreich, C. H., and Kreuzer, K. N. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J., 12: 2085-2097, 1993.
16. Bigioni, M., Zunino, F., and Capranico, G. Base mutational analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res., 22: 2274-2281, 1994.
17. Capranico, G., Palumbo, M., Tinelli, S., and Zunino, F. Unique sequence specificity of topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J. Biol. Chem., 269: 25004-25009, 1994.
18. Leteurtre, F., Fujimori, A., Tanizawa, A., Chabra, A., Mazumder, A., Kohlhagen, G., Nakano, H., and Pommier, Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem., 269: 28702-28707, 1994.
19. Gupta, M., Abdel-Megeed, M., Hoki, Y., Kohlhagen, G., Paull, K., and Pommier, Y. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol. Pharmacol., 48: 658-665, 1995.
20. Spitzner, J. R., Chung, I. K., Gootz, T. D., McGuirk, P. R., and Muller, M. T. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements. Mol. Pharmacol., 48: 238-249, 1995.
21. Capranico, G., Butelli, L., and Zunino, F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res., 55: 312-317, 1995.
22. De Isabella, P., Zunino, F., and Capranico, G. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic Acids Res., 23: 223-229, 1995.
23. Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol., 32: 103-108, 1993.
24. Freudenreich, C. H., and Kreuzer, K. N. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl. Acad. Sci. USA, 91: 11007-11011, 1994.
25. Kawada, S., Yamashita, Y., Fujii, N., and Nakano, H. Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin. and clerocidin. Cancer Res., 51: 2922-2925, 1991.
26. De Isabella, P., Capranico, G., Binaschi, M., Tinelli, S., and Zunino, F. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol. Pharmacol., 37: 11-16, 1990.
27. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J. Mol. Biol., 222: 909-924, 1991.
28. Tapper, D. P., and Clayton, D. A. Altered mobility of polydeoxyribonucleotides in high resolution polyacrylamide gels due to removal of terminal phosphates. Nucleic Acids Res., 9: 6787-6794, 1981.
29. Kawada, S., Yamashita, Y., Ochiai, K., Ando, K., Iwasaki, T., Takiguchi, T., and Nakano, H. Terpentecin and UCT4B, new family of topoisomerase II targeting antitumor antibiotics produced by Streptomyces: producing organism, fermentation and large scale purification. J. Antibiot. (Tokyo), 48: 211-216, 1995.
30. Nakajima, M., Okazaki, T., Iwada, S., Kinoshita, T., and Haneishi, T. New diterpenoid antibiotics, spirocardins A and B. J. Antibiot. (Tokyo), 42: 1741-1748, 1989.
31. Lee, M. P., and Hsieh, T. Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26. Nucleic Acids Res., 20: 5027-5033, 1992.
32. Rastrup Andersen, N., and Rassmussen, P. R. The relative and absolute configuration of clerocidin and its cometabolites. Tetrahedron Lett., 25: 469-172, 1984.
33. Macdonald, T. L., Lehnen, E. K., Loper, J. T., Chow, K-C., and Ross, W. E. On the mechanism of interaction of DNA topoisomerase II with chemotherapeutic agents. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 199-214. New York: Oxford University Press, 1991.
34. Zwelling, L. A., Mitchell, M. J., Satitpunwaycha, P., Mayes, J., Altschuler, E., Hinds, M., and Baguley, B. C. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development. Cancer Res., 52: 209-217, 1992.